Original scientific paper

https://doi.org/10.1515/acph-2017-0014

Effect of γ-ethyl-γ-phenyl-butyrolactone (EFBL), anticonvulsant and hypnotic drug, on mouse brain catecholamine levels

LOURDES A. VEGA RASGADO ; Laboratorio de Neuroquímica, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológica, Instituto Politécnico Nacional, Carpio y Plan de Ayala S/N, Colonia Casco de Santo Tomás, C.P. 11340, México, D.F., México
IVÁN VILLANUEVA ; Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Carpio y Plan de Ayala S/N, Colonia Casco de Santo Tomás, C.P. 11340, México, D.F., México
FERNANDO VEGA DÍAZ ; Laboratorio de Neuroquímica, Departamento de Bioquímica, Escuela Nacional de Ciencias Biológica, Instituto Politécnico Nacional, Carpio y Plan de Ayala S/N, Colonia Casco de Santo Tomás, C.P. 11340, México, D.F., México

Abstract

γ-Ethyl-γ-phenyl-butyrolactone (EFBL) is a structural combination of the anticonvulsant γ-hydroxy-γ-ethyl-γ-phenylbutyramide (HEPB) and the hypnotic γ-butyrolactone (GBL), which inherits both properties. To clarify its mechanism of action, the effects of EFBL, GBL and HEPB on dopamine (DA) and noradrenaline (NA) brain levels were investigated. Influences of chlorpromazine, phenelzine and amino-oxyacetic acid were also studied. EFBL increased DA in a dose-dependent manner, remaining enhanced by 80 % over a period of 24 h and augmented NA by 54 % one hour after treatment. HEPB increased DA and NA approximately 2-fold after the first hour. GBL raised DA and NA after three and 24 h, resp. EFBL reversed chlorpromazine effects but potentiated those of phenelzine on DA. Amino-oxyacetic modified neither DA nor NA brain levels, not even in the presence of EFBL. The anticonvulsant and hypnotic properties of EFBL are attributed to its effect on presynaptic dopaminergic receptors and its lasting effect on ethyl and phenyl radicals that hinder its degradation. The results support the role of DA and NA in regulating seizure activity in the brain and indicate that EFBL offers a potential treatment for refractory epilepsy without complementary drugs and Parkinson’s disease, without the drawbacks of oral therapies.

Keywords

γ-ethyl-γ-phenyl-butyrolactone (EFBL); anticonvulsant; hypnotic; mouse brain; catecholamines

Hrčak ID:

172754

URI

https://hrcak.srce.hr/172754

Publication date:

30.6.2017.

Visits: 1.516 *